Chronic infection with the hepatitis C virus. Comparison and Validation of Simple Noninvasive Tests for Prediction of Fibrosis in Chronic Hepatitis C
|
|
- Tyrone Ellis
- 5 years ago
- Views:
Transcription
1 Comparison and Validation of Simple Noninvasive Tests for Prediction of Fibrosis in Chronic Hepatitis C Carolin Lackner, 1 Gerd Struber, 1 Bernadette Liegl, 1 Sebastian Leibl, 1 Petra Ofner, 2 Csilla Bankuti, 3 Bernd Bauer, 4 and Rudolf E. Stauber 3 Liver biopsy is recommended before antiviral treatment, particularly for patients with hepatitis C virus (HCV) genotype 1 infection, but it may cause complications and is limited by sampling error. Several non-invasive tests comprising routine laboratory parameters (simple fibrosis tests) have been proposed to predict fibrosis in chronic HCV. The aim of the current study was to validate and compare the diagnostic accuracies of the simple fibrosis tests, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR), cirrhosis discriminant score (CDS), age-platelet (AP) index, Pohl score, AST-to-platelet ratio index (APRI), and platelet count per se. Staging was performed in liver biopsy specimens of 194 treatment-naïve patients with chronic HCV according to Ishak et al. by two independent pathologists. Receiver operating characteristic curve analysis showed comparable diagnostic accuracies of CDS, AP index, APRI, and platelet count for prediction of significant fibrosis (F3-F6) (area under the ROC curve [AUROC], 0.71, 0.74, 0.80, and 0.71, respectively; pathologist A) and for prediction of cirrhosis (F5-F6) (AUROC, 0.91, 0.91, 0.90, and 0.89, respectively; pathologist A). Diagnostic accuracy of APRI for prediction of significant fibrosis was superior to that of AAR (P <.05). Significant fibrosis was reliably predicted by APRI > 1.5 and platelet count < /L in 24% and 22% of the patients, respectively, whereas cirrhosis was reliably excluded by APRI <2.0 and platelet count > /L in 85% and 78% of the patients, respectively. In conclusion, simple fibrosis tests may render liver biopsy unnecessary only in a minority of patients with chronic HCV. Improved serum fibrosis markers with greater sensitivity for severe fibrosis or cirrhosis are needed. (HEPATOLOGY 2005;41: ) Chronic infection with the hepatitis C virus (HCV) is one of the most common causes of chronic liver disease in the western world and is complicated by cirrhosis or hepatocellular carcinoma in approximately 20% and 5% of patients, respectively. 1,2 Current antiviral treatment with pegylated interferon alfa Abbreviations: HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AAR, AST/ALT ratio; CDS, cirrhosis discriminant score; AP index, age-platelet index; APRI, AST-to-platelet ratio index; HAI, hepatic activity index; INR; international normalized ratio; ULN, upper limit of normal; ROC, receiver operating characteristic; PPV, positive predictive value; NPV, negative predictive value; AUROC, area under the ROC curve. From the 1 Department of Pathology, the 2 Institute for Medical Informatics, Statistics & Documentation; the 3 Department of Internal Medicine, Medical University Graz, Graz, Austria; and the 4 Department of Internal Medicine, Landeskrankenhaus Hoergas, Gratwein, Austria. Received November 23, 2004; accepted March 21, Address reprint requests to: Rudolf E. Stauber, M.D., Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, A-8036 Graz, Austria. rudolf.stauber@meduni-graz.at; fax: (43) Copyright 2005 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. plus ribavirin clears HCV infection in approximately 40% to 90% of patients, depending on HCV genotype. 3 Because antiviral treatment is costly and may be associated with significant side effects, the indication for antiviral therapy has to be evaluated carefully. Antiviral treatment is indicated for most patients infected with the easier-to-treat HCV genotypes 2 or 3. In contrast, the decision for treatment in the more difficult-to-treat HCV genotype 1 infected patients should be based on additional prognostic factors, such as the degree of hepatic fibrosis at the time of liver biopsy. Accordingly, recent American Association for the Study of Liver Diseases (AASLD) practice guidelines recommend antiviral treatment for patients with HCV genotype 1 infection only in cases with significant liver fibrosis (METAVIR fibrosis score 2/Ishak fibrosis score 3). 3 This concept is based on the finding that the risk of developing cirrhosis is closely related to the stage of fibrosis. 4 Liver biopsy is thus recommended to aid in the decision to treat patients infected with HCV genotype 1, but its value is being questioned because of its 1376
2 HEPATOLOGY, Vol. 41, No. 6, 2005 LACKNER ET AL potential risks and the concern of sampling error. 5 Therefore, noninvasive tests for hepatic fibrosis are desired by clinicians as well as patients. 6 Several laboratory tests, scores, and indices have been proposed for noninvasive prediction of hepatic fibrosis in patients with chronic hepatitis C Among these, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR), 7-12 cirrhosis discriminant score (CDS), 13 age-platelet index (AP index), 14 platelet count per se, 15 Pohl score, 16 and AST-to-platelet ratio index (APRI) 17 are based on routine laboratory parameters and therefore readily available in clinical practice. All of these tests were reported to predict the presence of significant fibrosis, bridging fibrosis, or cirrhosis with considerable diagnostic accuracies. However, discrepant results were reported for some of these tests when evaluated in different study populations. 24,25 The aim of the current study was to evaluate and compare diagnostic accuracies of AAR, CDS, AP index, Pohl score, APRI, and platelet count for the prediction of significant fibrosis or cirrhosis. Patients and Methods The study cohort included 211 consecutive patients with chronic hepatitis C who underwent percutaneous liver biopsy at the Medical University Graz or at the Landeskrankenhaus Hoergas, Austria, between 1994 and All patients tested positive for the presence of HCV RNA using a polymerase chain reaction assay and did not suffer from additional causes of chronic liver disease as confirmed by standard clinical, serological, biochemical, and radiological criteria. Additional exclusion criteria were antiviral treatment before liver biopsy, alcohol consumption in excess of 20 g/d, and previous liver transplantation. Liver tissues were fixed in formalin immediately after biopsy and embedded in paraffin; 4- m sections were cut with a microtome. One section of each biopsy was stained with hematoxylin-eosin for assessment of hepatic inflammatory activity and the other section with the chromotrope aniline blue for evaluation of hepatic fibrosis. Biopsy specimens with at least six portal fields were considered representative. 5 Seventeen patients whose biopsy specimens showed fewer than six portal fields were excluded, leaving 194 patients for analysis. Histological grading (modified hepatic activity index [HAI]) and staging (fibrosis score) were performed independently by two pathologists (pathologist A, C.L.; pathologist B, S.L. or B.L.) as described by Ishak et al. 26 AST, ALT, prothrombin time (international normalized ratio [INR]), and platelet count were routinely determined Fibrosis test Table 1. Simple Fibrosis Tests Composed of Routine Laboratory Parameters Calculation AAR AST/ALT CDS Platelet count ( 10 9 /L): 340 0; ; ; ; ; ; 40 6 ALT/AST ratio: 1.7 0; ; ; INR: 1.1 0; ; CDS is the sum of the above (possible value 0 11). AP index Age (years): 30 0; ; ; ; ; 70 5 Platelet count ( 10 9 /L): 225 0; ; ; ; ; AP index is the sum of the above (possible value 0 10). Pohl score Positive: AAR 1 and platelet count /L APRI ([AST/ULN]/platelet count [ 10 9 /L]) 100 Abbreviations: AAR, AST/ALT ratio; CDS, cirrhosis discriminant score; AP index, age-platelet index; APRI, AST-to-platelet ratio index; ULN, upper limit of normal. in the clinical laboratory. Because of the introduction of the International Federation of Clinical Chemistry reference method for the determination of aminotransferase activities at 37 C, the upper limits of normal (ULN) for AST and ALT changed in the course of the study (ULN before March 2003: AST, 18 U/L; ALT, 22 U/L; after March 2003: AST, 35 U/L or 30 U/L, ALT, 45 U/L or 35 U/L ). Therefore, both AST and ALT were transformed into multiples of the ULN for further analysis except for the calculation of AAR. The reference range for platelet count was 140 to /L. Laboratory parameters were available on the day of liver biopsy (n 96) or from within 1 month of the date of liver biopsy (n 98). From these routine laboratory values, AAR, CDS, AP index, Pohl score, and APRI were calculated exactly as originally described 13,14,16,17 (Table 1). Statistical analysis was performed using the SPSS software version 11.0 (SPSS Inc., Chicago, IL). Patient characteristics are given as mean SD or median and interquartile range as appropriate. Bivariate Spearman s rank correlation coefficient (R) was calculated to measure the relationship between variables. Kappa statistics was used to measure agreement between the two pathologists in determining the degree of fibrosis. Receiver operating characteristic (ROC) curves were constructed for each test. To evaluate diagnostic accuracies of simple fibrosis tests, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the area under the receiver operating characteristic curve (AUROC) were calculated. Individual AUROCs of continuous variables, such as AAR, APRI, and platelet count, were compared according to the procedure proposed by Hanley and McNeil. 27
3 1378 LACKNER ET AL. HEPATOLOGY, June 2005 Table 2. Characteristics of the Study Population (n 194) Age, yrs Male sex, n (%) 111 (57%) Genotype 1, n (%) 119 (84%) BMI AST/ULN ALT/ULN Prothrombin time (INR) Platelet count ( 10 9 /L) Length of biopsy core (mm) 19 8 Number of portal tracts, median (Q1, Q3) 11 (9, 16) Results Modified HAI score, median (Q1, Q3) 6 (4, 7) 5 (4, 6) Mild (0 6), n Moderate (7 12), n Severe (13 18), n 0 0 Ishak fibrosis score, median (Q1, Q3) 2.5 (1, 4) 2 (1, 3) F0, n 3 1 F1, n F2, n F3, n F4, n F5, n F6, n NOTE. Results are given as means SD, unless indicated otherwise. Abbreviations: BMI, body mass index; ULN, upper limit of normal; INR, international normalized ratio; Q1, first quartile; Q3, third quartile. Clinical characteristics of the patients and standard laboratory tests at the time of liver biopsy are summarized in Table 2. HCV genotype was known in 141 patients. Genotype 1 was present in 119 patients, genotype 2 in 3 patients, genotype 3 in 10 patients, and genotype 4 in 9 patients. Ishak s modified HAI ranged from 1 to 11. Significant fibrosis (F3-F6) was found in 50% or 46% and cirrhosis (F5-F6) in 16% or 17% of patients (pathologist A or B, respectively). Good agreement was found between pathologists A and B for the Ishak fibrosis score in predicting significant fibrosis (Kappa 0.79) and cirrhosis (Kappa 0.93). Weak to moderate correlations were found between HAI versus AST, ALT, and INR, respectively (Table 3). Table 4. Correlation of Stage (Ishak Fibrosis Score) with Standard Laboratory Parameters and Simple Fibrosis Tests Ishak Fibrosis Score vs. Bivariate Spearman s Rank Correlation Coefficient AST/ULN 0.54* 0.51* ALT/ULN 0.40* 0.36* INR 0.40* 0.37* Platelet count 0.50* 0.46* AAR CDS 0.46* 0.46* AP index 0.53* 0.52* APRI 0.62* 0.60* Abbreviations: ULN, upper limit of normal; INR, international normalized ratio; AAR, AST/ALT ratio; CDS, cirrhosis discriminant score; AP index, age-platelet index; APRI, AST-to-platelet ratio index. *P.001. P.05. Hepatic fibrosis weakly correlated with ALT, INR, AAR, and CDS, whereas moderate correlations were found with AST, platelet count, AP index, and APRI (Table 4). ROC curves evaluating the diagnostic accuracies of AAR, CDS, AP index, APRI, and platelet count were constructed to predict significant fibrosis (Fig. 1) or cirrhosis (Fig. 2). Comparison of AUROCs for continuous variables (AAR, APRI, and platelet count) by the procedure proposed by Hanley and McNeil 27 showed superior diagnostic accuracy of APRI over AAR for prediction of significant fibrosis (Table 5). Similar results were found for all correlations and ROC analyses when hepatic fibrosis was assessed by either pathologist A or B (Tables 3-5). To compare our results with those of the previous publications, sensitivity, specificity, PPV, and NPV of simple Table 3. Correlation of Grade (Modified Hepatic Activity Index) With Standard Laboratory Parameters Modified HAI vs. Bivariate Spearman s Rank Correlation Coefficient AST/ULN 0.48* 0.52* ALT/ULN 0.46* 0.51* INR 0.29* 0.25 Abbreviations: ULN, upper limit of normal; INR, international normalized ratio. *P.001. P.01. Fig. 1. Receiver operating characteristic (ROC) curves of five simple noninvasive tests for prediction of significant fibrosis (F3-F6) according to the Ishak system in 194 patients with chronic hepatitis C. ROC curves are shown for fibrosis stage assessed by pathologist A. AAR, AST/ALT ratio; CDS, cirrhosis discriminant score; AP index, age-platelet index; APRI, AST to-platelet ratio index.
4 HEPATOLOGY, Vol. 41, No. 6, 2005 LACKNER ET AL (F4-F6) in only 2% of the patients. Conversely, a platelet count of /L or greater or an APRI of less than 2.0 reliably excluded cirrhosis in 78% or 85% of the patients, respectively. Overall the performance of AP index, Pohl score, and APRI in our study was in good agreement with the data reported by Poynard et al., 14 Pohl et al., 16 and Wai et al., 17 respectively. In contrast, PPV of AAR and platelet count (cutoff /L) for cirrhosis was considerably lower in our study than in the report by Giannini et al. 12 (Table 6). Fig. 2. Receiver operating characteristic (ROC) curves of five simple noninvasive tests for prediction of cirrhosis (F5-F6) according to the Ishak system in 194 patients with chronic hepatitis C. ROC curves are shown for fibrosis stage assessed by pathologist A. AAR, AST/ALT ratio; CDS, cirrhosis discriminant score; AP index, age-platelet index; APRI, AST-toplatelet ratio index. fibrosis tests were calculated for each pathologist s staging using categories and cutoff values exactly as originally described (Table 6). For platelet count, an optimal cutoff of /L was determined by ROC analysis. High PPVs for significant fibrosis and high NPVs for cirrhosis were found with platelet count as well as APRI. Platelet count per se demonstrated high predictive values for both diagnosis of significant fibrosis (PPV 93%, pathologists A and B, respectively) and exclusion of cirrhosis (NPV 95%, pathologists A and B, respectively) at the same cutoff level of /L. Similarly, an APRI 1.5 had a PPV of 91% or 83% (pathologist A or B, respectively) for significant fibrosis, whereas an APRI 2.0 had an NPV of 91% (pathologists A and B, respectively) for cirrhosis. A platelet count of less than /L or an APRI of 1.5 or greater allowed reliable diagnosis of significant fibrosis in 22% or 24% of our patients, respectively (i.e., in about half of the patients with true significant fibrosis) whereas a CDS of 8 or higher was diagnostic for bridging fibrosis Discussion Several routine laboratory parameters, used either alone or in combination, have been evaluated as noninvasive predictors of hepatic fibrosis In addition, special fibrosis markers such as hyaluronic acid 19 and several multicomponent tests such as a five-marker index composed of 2-macroglobulin, apolipoprotein A1, haptoglobin, total bilirubin, and gamma-glutamyl-transpeptidase (Fibrotest, Biopredictive, France) 21,22 or, more recently, an algorithm combining age, hyaluronic acid, amino-terminal propeptide of type III collagen, and tissue inhibitor of matrix metalloproteinase 1 23 were proposed for non-invasive diagnosis of hepatic fibrosis. Assessment of these special markers is, however, costly and not routinely available in most clinical laboratories. All noninvasive fibrosis tests evaluated in the current study (AAR, CDS, AP index, Pohl score, and APRI) are derived from four readily available laboratory parameters, that is, AST, ALT, platelet count, and prothrombin time (INR). Simple fibrosis tests are not yet widely applied in clinical practice and recent AASLD guidelines on diagnosis and treatment of chronic hepatitis C do not include recommendations for their use. 3 This may be related to the fact that their diagnostic accuracies have not yet been sufficiently validated by other investigators in different study populations. In the current study, we confirm diagnostic accuracies at the reported cutoffs for CDS, AP in- Table 5. Performance of Simple Fibrosis Tests for Prediction of Significant Fibrosis (F3 F6) or Cirrhosis (F5 F6) Ishak Fibrosis Score vs. AUROC (F3 F6) AUROC (F5 F6) AUROC (F3 F6) AUROC (F5 F6) AAR 0.57 ( ) 0.73* ( ) 0.57 ( ) 0.75* ( ) CDS 0.71* ( ) 0.91* ( ) 0.73* ( ) 0.90* ( ) AP index 0.74* ( ) 0.91* ( ) 0.75* ( ) 0.91* ( ) APRI 0.80* ( ) 0.90* ( ) 0.80* ( ) 0.90* ( ) Platelet count 0.71* ( ) 0.89* ( ) 0.71* ( ) 0.90* ( ) Abbreviations: AUROC, area under the receiver operating characteristic curve (confidence intervals are given in parentheses); AAR, AST/ALT ratio; CDS, cirrhosis discriminant score; AP index, age-platelet index; APRI, AST-to-platelet ratio index. *P.05 vs. AUROC 0.5. P.05 vs. AAR (comparison of AUROCs according to Hanley and McNeil 27 ).
5 1380 LACKNER ET AL. HEPATOLOGY, June 2005 Table 6. Diagnostic Accuracies of Simple Fibrosis Tests for Prediction of Significant Fibrosis (F3 F6), Bridging Fibrosis (F4 F6), and Cirrhosis (F5 F6) Ishak Fibrosis Score Noninvasive Test Cutoff Patients Classified (%) Diagnostic Accuracy (%) F3 F6 F4 F6 F5 F6 /B (literature) AAR Sensitivity 36/36 (78) Specificity 90/90 (97) PPV 41/41 (93) NPV 87/87 (89) CDS 8 2 Sensitivity 10/11 (46) Specificity 100/100 (98) PPV 100/100 (n/a) NPV 77/79 (n/a) AP index 6 29 Sensitivity 51/51 (45) Specificity 93/90 (96) PPV 87/81 (96) NPV 66/68 (42) Pohl score Positive 6 Sensitivity 18/22 (41) Specificity 98/99 (99) PPV 73/82 (93) NPV 77/81 (85) APRI Sensitivity 88/88 (91) Specificity 44/42 (47) PPV 60/56 (61) NPV 80/80 (86) Sensitivity 44/43 (41) Specificity 96/93 (95) PPV 91/83 (88) NPV 64/65 (64) Sensitivity 93/93 (89) Specificity 70/70 (75) PPV 38/38 (38) NPV 98/98 (98) Sensitivity 55/52 (57) Specificity 93/92 (93) PPV 59/56 (57) NPV 91/91 (93) Platelet count /L 15 Sensitivity 30/32 53/53 (91) Specificity 100/100 93/93 (88) PPV 100/100 59/59 (81) NPV 59/63 91/91 (95) /L 22 Sensitivity 42/45 77/77 Specificity 97/97 88/88 PPV 93/93 56/56 NPV 63/67 95/95 NOTE. Data are shown for Ishak fibrosis score as assessed by pathologist A or B (values reported in the original studies are given in parentheses). The cutoffs described in the original reports were used for all calculations. For AAR and platelet count, Ishak stages F5-F6 in our study were compared with presence of cirrhosis in the Giannini study 12 ; for CDS, Ishak stages F4-F6 in our study were compared with modified Knodell stages F3-F4 in the Bonacini study 13 ; for AP index, Ishak stages F3-F6 in our study were compared with METAVIR stages F2-F4 in the Poynard study 14 ; and for Pohl score, Ishak stages F4-F6 in our study were compared with METAVIR stages F3-F4 in the Pohl study. 16 Abbreviations: AAR, AST/ALT ratio; CDS, cirrhosis discriminant score; AP index, age-platelet index; APRI, AST-to-platelet ratio index; PPV, positive predictive value; NPV, negative predictive value. dex, Pohl score, and APRI but not AAR for significant fibrosis or cirrhosis. It should be pointed out that platelet count per se had similar diagnostic accuracies as the other simple fibrosis tests comprising platelet count among other laboratory parameters. Consistent with our findings, Wai et al. 17 also reported low diagnostic accuracy of AAR in predicting significant fibrosis (AUROC 0.60) and cirrhosis (AUROC 0.76) (Giannini and Testa, 24 author reply). Differences in the study populations and the histopathological assessment of fibrosis may be responsible for these discrepancies. For example, prevalence of cirrhosis was 36% in the population studied by Giannini et al. 12 but only 15% in the Wai study 17 and 16% to 17% in our study. In the Giannini study, cirrhosis was mainly diagnosed on the basis of clinical signs of portal hypertension (and not on histology),
6 HEPATOLOGY, Vol. 41, No. 6, 2005 LACKNER ET AL indicating more advanced cirrhosis in their patients. Furthermore, it should be pointed out that four different staging systems were used in the respective studies: Giannini et al. used the Scheuer system, 28 Bonacini et al. applied a modified Knodell system, 29 Poynard et al. and Pohl et al. used the METAVIR system, 30 and the Ishak system 26 was used in the Wai study and in our study. Comparison between these studies is further hampered by the fact that the different staging systems use either a 5-step (F0-F4) or a 7-step (F0-F6) scale, even though good agreement of staging by the METAVIR and Ishak systems was recently reported. 31 In contrast to the other tests, APRI uses 2 different cutoff values for exclusion or prediction of significant fibrosis ( 0.5/ 1.5) and thus allowed reliable diagnosis or exclusion of significant fibrosis in approximately 50% of patients in the study by Wai et al. 17 We could confirm a high PPV for significant fibrosis of an APRI 1.5 in 24% of our patients; however, the NPV of an APRI 0.5 for exclusion of significant fibrosis was found to be slightly lower (80% vs. 86% in the Wai et al. study). This discrepancy may be attributable to differences in the study populations. APRI was recently evaluated in a large cohort of treatment-naive patients with chronic hepatitis C undergoing various clinical trials. 25 The diagnostic accuracy of APRI in predicting hepatic fibrosis or cirrhosis was somewhat lower than in the Wai study and in our study. This may be related to the use of different staging systems (the Scheuer system vs. the Ishak system) and to the fact that histology was assessed by several pathologists in different trial centers as opposed to one single pathologist in the Wai study or two independent pathologists in our study. The inverse correlation of platelet count and the degree of hepatic fibrosis in chronic hepatitis C has been noted by several investigators Thrombocytopenia in patients with advanced hepatic fibrosis may be explained by portal hypertension leading to pooling of platelets in an enlarged spleen, a myelosuppressive action of HCV, or reduced hepatic production of thrombopoietin. 32 However, only a few studies have assessed the diagnostic value of platelet count per se for prediction of hepatic fibrosis in chronic hepatitis C. 12,15,20,22 Comparison of these studies with our findings is again hampered by differences in the study design and staging systems. Murawaki et al. 20 evaluated 165 patients with chronic hepatitis C and fibrosis stages F0-F3 (Scheuer system) and reported that the platelet count at a cutoff of /L was 68% sensitive and 71% specific for prediction of F2-F3 fibrosis. 20 Giannini et al. 12 reported high diagnostic accuracy of platelet count for prediction of cirrhosis at a cutoff level of /L. However, at this cutoff we found a lower sensitivity and PPV of platelet count for prediction of cirrhosis (Table 6), which may be explained by differences in the composition of the study cohort. Myers et al. 22 compared diagnostic accuracies of Fibrotest, prothrombin time, platelet count, and AP index in 323 patients with chronic hepatitis C and reported an AUROC of 0.67 for platelet count and of 0.72 for AP index for prediction of F2-F4 fibrosis (METAVIR system), which correspond well to our findings. 22 Based on a comprehensive systematic review, Gebo et al. 33 concluded that biochemical blood tests and serologic tests have only modest value in predicting fibrosis on liver biopsy. We agree that the moderate diagnostic accuracy of simple fibrosis tests for intermediate stages of fibrosis limits their application. Overall, the simple fibrosis tests evaluated in this study were less accurate for prediction of significant fibrosis than for prediction of cirrhosis, and none of them were found to reliably exclude significant fibrosis. Nevertheless, both APRI 1.5 and platelet count /L can identify significant fibrosis with a PPV 90% in subsets of patients with chronic hepatitis C. In summary, by using specific cutoff points, clinically important stages of chronic hepatitis C can be reliably identified without a liver biopsy: (1) significant fibrosis can be predicted in approximately 25%, and (2) cirrhosis can be excluded in approximately 80% of patients typically seen in a referral center. Acknowledgment: The authors thank Profs. Helmut Denk and Gerald Hoefler for fruitful discussion of the manuscript. References 1. EASL international consensus conference on hepatitis C: Paris, February 1999: consensus statement. J Hepatol 1999;31(Suppl 1): National Institutes of Health consensus development conference statement: management of hepatitis C: 2002-June 10-12, HEPATOLOGY 2002;36(Suppl 1):S3-S Strader DB, Wright T, Thomas DL, Seeff LB. AALSD practice guideline: diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23: Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003;38: Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C (review). HEPATOLOGY 2002;36(Suppl 1):S57-S Williams ALB, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. Gastroenterology 1988;95: Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93: Reedy DW, Loo AT, Levine RA. AST/ALT ratio 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998;43: Park GJH, Lin BPC, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase : alanine aminotransferase ratio in chronic hepatitis C infection:
7 1382 LACKNER ET AL. HEPATOLOGY, June 2005 is it a useful predictor of cirrhosis? J Gastroenterol Hepatol 2000;15: Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000;95: Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997;92: Poynard T, Bedossa P, METAVIR and CLINIVIR cooperative study groups. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepatol 1997;4: Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, et al. Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999;15: Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96: Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003;38: Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002;36: Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepatol 1998;5: Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001;16: Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357: Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T; MULTIVIRC Group. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and AP index. Dig Dis Sci 2003;48: Rosenberg WMC, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127: Giannini E, Testa R. Noninvasive diagnosis of fibrosis: the truth is rarely pure and never simple [Letter]. HEPATOLOGY 2003;38: ; author reply Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, et al. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? [Letter]. HEPATOLOGY 2004;39: ; author reply Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22: Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148: Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994;19: Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOL- OGY 1981;1: The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. HEPATOLOGY 1994;20: Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol 2003;38: Peck-Radosavljevic M. Hypersplenism. Eur J Gastroenterol Hepatol 2001; 13: Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. HEPATOLOGY 2002;36(Suppl 1):S161-S172.
Simple Tests to Predict Hepatic Fibrosis in Nonalcoholic Chronic Liver Diseases
Gut and Liver, Vol. 1, No. 2, December 2007, pp. 145-150 original article Simple Tests to Predict Hepatic Fibrosis in Nonalcoholic Chronic Liver Diseases Woon Geon Shin*, Sang Hoon Park*, Sun-Young Jun,
More informationAspartate Aminotransferase-to-Platelet Ratio Index for Fibrosis and Cirrhosis Prediction in Chronic Hepatitis C Patients
BJID 2008; 12 (February) 15 Aspartate Aminotransferase-to-Platelet Ratio Index for Fibrosis and Cirrhosis Prediction in Chronic Hepatitis C Patients Roberto Gomes da Silva Junior 1, Ricardo Fakhouri 2,
More informationAbstract INTRODUCTION RAPID COMMUNICATION
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 December 14; 14(46): 7117-7121 wjg@wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 doi:10.3748/wjg.14.7117 2008 The WJG Press.
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationHepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection
Papers in Press. First published July 28, 2005 as doi:10.1373/clinchem.2005.048389 Clinical Chemistry 51:10 000 000 (2005) General Clinical Chemistry Hepascore: An Accurate Validated Predictor of Liver
More informationPrediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis
The Korean Journal of Hepatology 2010;16:369-375 DOI: 10.3350/kjhep.2010.16.4.369 Original Article Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationUsefulness of Non-invasive Markers for Predicting Significant Fibrosis in Patients with Chronic Liver Disease
J Korean Med Sci 21; 25: 67-74 ISSN 111-8934 DOI: 1.3346/jkms.21.25.1.67 Usefulness of Non-invasive Markers for Predicting Significant Fibrosis in Patients with Chronic Liver Disease The purpose of this
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Validity and Clinical Utility of the Aspartate Aminotransferase Alanine Aminotransferase Ratio in Assessing Disease Severity and Prognosis in Patients With Hepatitis C Virus Related
More informationPretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy
Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Teerha Piratvisuth MD. Prince of Songkla University Treatment of chronic hepatitis C and response rates
More informationThe role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases
RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment
More informationEvaluation of Fibrosis Progression by Noninvasive Biochemical Markers in Egyptian Patients with Chronic Hepatitis B
EJOHG 10.5005/jp-journals-10018-1016 Evaluation of Fibrosis Progression by Noninvasive Biochemical Markers in Egyptian Patients with Chronic Hepatitis B ORIGINAL ARTICLE Evaluation of Fibrosis Progression
More informationSerum alanine aminotransferase has limited predictive value for liver disease in chronic hepatitis C
European Review for Medical and Pharmacological Sciences Serum alanine aminotransferase has limited predictive value for liver disease in chronic hepatitis C S.A. ARAIN 1, S. YAEESH 2, S.A. MEO 3, Q. JAMAL
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More information*Khairy H Morsy, Mahmoud Saif -Al-Islam, Amr A Hamed
ARC Journal of Hepatology and Gastroenterology Volume 2, Issue 1, 2017, PP 4-12 www.arcjournals.org Evaluation of Aspartate Aminotransferase Platelets Ratio Index (APRI) and FIB-4 as Non Invasive Predictors
More informationAspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis
The Turkish Journal of Pediatrics 2015; 57: 492-497 Original Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis Aysel Ünlüsoy-Aksu 1,
More informationPatients and Methods. study was conducted according to the Declaration of Helsinki.
SAFE Biopsy: A Validated Method for Large-Scale Staging of Liver Fibrosis in Chronic Hepatitis C Giada Sebastiani, 1 Philippe Halfon, 2 Laurent Castera, 3 Stanislas Pol, 4 David L. Thomas, 5 Alessandra
More informationFibroScore for the Non-invasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis
ORIGINAL ARTICLE FibroScore for the Non-invasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis Shahzad Ashraf 1, Syed Azhar Ahmed 2, Jameel Ahmed 3 and Nadir Ali 4 ABSTRACT Objective: To evaluate
More informationPercutaneous needle biopsy of the liver is an important
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:930 935 Importance of Specimen Size in Accurate Needle Liver Biopsy Evaluation of Patients With Chronic Hepatitis C THOMAS D. SCHIANO,* SAMIA AZEEM,* CAROL
More information/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT
原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4
More informationThe diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients
1130-0108/2015/107/12/740-744 Revista Española de Enfermedades Digestivas Copyright 2015 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid) Vol. 107, N.º 12, pp. 740-744, 2015 ORIGINAL PAPERS The diagnostic
More informationAlternatives to Liver Biopsy for Assessing Liver Disease
Alternatives to Liver Biopsy for Assessing Liver Disease a report by Thierry Poynard Professor of Medicine, University of Paris The consensus conference statements recommend liver biopsy in the management
More informationThe predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C
The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C LIVER Hale Gökcan 1, Ufuk Barış Kuzu 1, Erkin Öztaş 1, Fatih Saygılı 1, Derya Öztuna 2, Nuretdin
More informationSection: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013
Medical Policy Manual Topic: Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Date of Origin: June 2013 Section: Laboratory Last Reviewed
More informationMultianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease.
2.04.41 Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date September
More informationInvasive. Sampling error. Interobserver variability. Nondynamic evaluation of
How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationJournal of Asian Scientific Research
Journal of Asian Scientific Research journal homepage: http://aessweb.com/journal-detail.php?id=5003 COULD SERUM LAMININ REPLACE LIVER BIOPSY AS GOLD STANDARD FOR PREDICTING SIGNIFICANT FIBROSIS IN PATIENTS
More informationMonitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
More informationAssessment of Liver Fibrosis and Cirrhosis by Aspartate Aminotransferase-to-Platelet Ratio Index in Children With Biliary Atresia
ORIGINAL ARTICLE: HEPATOLOGY AND NUTRITION Assessment of Liver Fibrosis and Cirrhosis by Aspartate Aminotransferase-to-Platelet Ratio Index in Children With Biliary Atresia Sang Yong Kim, y Jae Yeon Seok,
More informationNoninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2018 Origination: 2/2017 Next Review: 2/2019 Policy Blue Cross and
More informationPrediction of liver fibrosis in HIV/HCV-coinfected patients by simple noninvasive indexes[0]
Gut Online First, published on August 23, 2005 as 10.1136/gut.2005.065904 1 Prediction of liver fibrosis in HIV/HCV-coinfected patients by simple noninvasive indexes[0] Authors: Juan Macías 1, 6, José
More informationSection: Laboratory Last Reviewed Date: May Policy No: 47 Effective Date: August 1, 2014
Medical Policy Manual Topic: Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Date of Origin: June 2013 Section: Laboratory Last Reviewed
More informationDIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY.
Gut Online First, published on July 14, 2005 as 10.1136/gut.2005.069153 DIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY. Juliette Foucher (1), Elise Chanteloup (1), Julien
More informationThe New World of HCV Therapy
HCV: Assessing the Patient Prior to Treatment: Diagnostic Testing and Strategy JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The New World of HCV Therapy Interferon-free
More informationTS, Lin YH. Routine blood tests to predict liver fibrosis in
Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v18.i8.746 World J Gastroenterol 2012 February 28; 18(8): 746-753 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationWhen to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
More information"Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C
Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v17.i41.4607 World J Gastroenterol 2011 November 7; 17(41): 4607-4613 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
More informationPage: 1 of 19. Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease
and Monitoring of Patients with Chronic Liver Page: 1 of 19 Last Review Status/Date: March 2015 and Monitoring of Patients with Chronic Liver Description Options for noninvasive monitoring of liver fibrosis
More informationNoninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2019 Origination: 2/2017 Next Review: 2/2020 Policy Blue Cross and
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationMultianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease
Medical Policy Manual Laboratory, Policy No. 47 Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Next Review: May 2018 Last Review:
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationThe Future is Here Now!
HCV Treatment: Assessing the Patient Prior to Treatment. How Will This Change in the Future? JORGE L. HERRERA M.D., FACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The Future is Here Now!
More informationLaboratory and Clinical Diagnosis of HCV Infection
Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests
More informationTransient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases
Journal of Viral Hepatitis, 2007, 14, 360 369 doi:10.1111/j.1365-2893.2006.00811.x Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases B. Coco,
More informationAlam MM 1, Mahtab MA 1, Akbar SMF 2, Kamal M 3, Rahman S 1
Bangladesh Med Res Counc Bull 2014; 40: 92-56 Hepatic necroinflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase
More informationFibro-check: a combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients
Fibro-check., 2015; 14 (2): 225-233 ORIGINAL ARTICLE March-April, Vol. 14 No. 2, 2015: 225-233 225 Fibro-check: a combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis
More informationAlimentary Pharmacology and Therapeutics SUMMARY
Alimentary Pharmacology and Therapeutics The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411
More informationCORRELATION BETWEEN BIOCHEMICAL AND HISTOPATHOLOGICAL PARAMETERS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
Psychiatria Danubina, 2014; Vol. 26, Suppl. 2, pp S364 S369 Medicina Academica Mostariensia, 2014; Vol. 2, No. 1-2, pp 8-13 Medicinska naklada - Zagreb, Croatia Original paper CORRELATION BETWEEN BIOCHEMICAL
More informationHepatitis C virus (HCV) causes deaths
Original Article / Liver Hepatobiliary & Pancreatic Diseases International Diagnostic accuracy of enhanced liver test to assess liver in patients with chronic hepatitis C Roberto Catanzaro, Michele Milazzo,
More informationC-Galactose Breath Test and 13 C-Aminopyrine Breath Test for the Study of Liver Function in Chronic Liver Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:279 285 C-Galactose Breath Test and C-Aminopyrine Breath Test for the Study of Liver Function in Chronic Liver Disease EDOARDO G. GIANNINI,* ALBERTO FASOLI,*
More informationXiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi;
Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 3743427, 6 pages http://dx.doi.org/10.1155/2016/3743427 Research Article The Score Model Containing Chinese Medicine Syndrome
More informationTitle: The Baveno VI criteria for predicting esophageal varices: validation in real life practice
Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice Authors: Mafalda Sousa, Sónia Fernandes, Luísa Proença, Ana Paula Silva, Sónia Leite, Joana Silva, Ana
More informationFibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B
Zeremski et al. BMC Gastroenterology 2014, 14:118 RESEARCH ARTICLE Open Access FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B Marija Zeremski 1*, Rositsa B
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Noninvasive Techniques for the Evaluation and Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation and Professional
More informationNoninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD
Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis
More informationComparison between FIB-4 Index and Fibroscan as Marker of Fibrosis in Chronic HCV Infection in Egyptian Patients
Open Journal of Gastroenterology, 2014, 4, 383-391 Published Online December 2014 in SciRes. http://www.scirp.org/journal/ojgas http://dx.doi.org/10.4236/ojgas.2014.412052 Comparison between FIB-4 Index
More informationIntermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or pathologists expertise
652 Chindamo MC, et al., 2015; 14 (5): 652-657 ORIGINAL ARTICLE September-October, Vol. 14 No. 5, 2015: 652-657 Intermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or
More informationTransient elastography is a new tool for assessing. Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC
Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC Christophe Corpechot, 1 Ahmed El Naggar, 1 Armelle Poujol-Robert, 1 Marianne Ziol, 2 Dominique Wendum, 3 Olivier Chazouillères,
More informationSojan George Kunnathuparambil, Kattoor Ramakrishnan Vinayakumar, Mahesh R. Varma, Rony Thomas, Premaletha Narayanan, Srijaya Sreesh
Original article Annals of Gastroenterology (2013) 26, 1-5 Bilirubin, aspartate aminotransferase and platelet count score: a novel score for differentiating patients with chronic hepatitis B with acute
More informationHEP DART 2017, Kona, Hawaii
HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George
More informationInternational Journal of Integrative Biology A journal for biology beyond borders ISSN
Report International Journal of Integrative Biology A journal for biology beyond borders ISSN 973-8363 to diagnose fibrosis in patients with chronic active Hepatitis C Mosa T E 1, Abd El-Maksoud M D 1,*,
More informationOriginal article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients
Antiviral Therapy 2011; 16:165 172 (doi: 10.3851/IMP1726) Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Grace Lai-Hung Wong 1,2,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationS ince the discovery of hepatitis C, there have been several
402 ORIGINAL ARTICLE Steatosis and fibrosis in patients with chronic hepatitis C J Wyatt, H Baker, P Prasad, Y Y Gong, C Millson... See end of article for authors affiliations... Correspondence to: Dr
More informationLiver enzyme normalization predicts success of Hepatitis C oral directacting antiviral treatment
ORIGINAL RESEARCH Sarwat T. Khan, B.Sc. 1,2 Michaeline McGuinty, M.D. 2 Daniel J. Corsi, Ph.D. 2 Curtis L. Cooper, M.D. 1,2 1University of Ottawa, Ottawa, Canada 2The Ottawa Hospital Research Institute,
More informationResearch Article Accurate Prediction of Advanced Liver Fibrosis Using the Decision Tree Learning Algorithm in Chronic Hepatitis C Egyptian Patients
Gastroenterology Research and Practice Volume 2016, Article ID 2636390, 7 pages http://dx.doi.org/10.1155/2016/2636390 Research Article Accurate Prediction of Advanced Liver Fibrosis Using the Decision
More informationMarek Woynarowski, Joanna Cielecka-Kuszyk, Andrzej Kałużyński, Aleksandra Omulecka, Maria Sobaniec-Łotowska, Julian Stolarczyk, Wojciech Szczepański
PO Box 2345, Beijing 23, China World J Gastroenterol 6 March 21; 12(11): 1713-1717 World Journal of Gastroenterology ISSN 7-9327 wjg@wjgnet.com 6 The WJG Press. All rights reserved. VIRAL HEPATITIS Inter-observer
More informationFaculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
More informationLiver 102: Injury and Healing
Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More information*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor
APPENDIX 1 LIST OF COINVESTIGATORS *APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor M Vidaud; Hôpital Cochin-Necker: Professor S Pol, Professor Ph Sogni, Professor
More informationAn important component of management of hepatitis. Noninvasive Monitoring of Patients With Chronic Hepatitis C. Robert J. Fontana and Anna S. F.
Noninvasive Monitoring of Patients With Chronic Hepatitis C Robert J. Fontana and Anna S. F. Lok Hepatic fibrosis is the main determinant of clinical outcomes of chronic hepatitis C. Liver histology is
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Noninvasive Techniques for the Evaluation and Monitoring of Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation
More informationMP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease
Medical Policy BCBSA Ref. Policy: 2.04.41 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 9.01.502 Experimental / Investigational Services DISCLAIMER Our medical policies
More informationThe New World of HCV Therapy
HCV: Assessing the Patient Prior to Treatment: Diagnostic Testing and Strategy JORGE L. HERRERA M.D., MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL The New World of HCV Therapy Interferon-free
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationManagement of Incidental Hepatitis C Virus Infection
The new england journal of medicine Clinical Decisions Interactive at nejm.org Management of Incidental Hepatitis C Virus Infection This interactive feature addresses the diagnosis or management of a clinical
More informationThe FibroTest Value in Discriminating between Insignificant and Significant Fibrosis in Chronic Hepatitis C Patients. The Romanian Experience
Fibrotest for discriminating fibrosis severity in chronic hepatitis C The FibroTest Value in Discriminating between Insignificant and Significant Fibrosis in Chronic Hepatitis C Patients. The Romanian
More informationJournal of the Egyptian Society of Parasitology, Vol.46, No.1, April 2016 J. Egypt. Soc. Parasitol. (JESP), 46(1), 2016:
Journal of the Egyptian Society of Parasitology, Vol.46, No.1, April 2016 J. Egypt. Soc. Parasitol. (JESP), 46(1), 2016: 125-130 SERUM MARKERS FOR ASSESSING LIVER FIBROSIS IN EGYPTIAN PA- TIENTS WITH CHRONIC
More informationIn chronic liver disease, the gradual accumulation of hepatic
GASTROENTEROLOGY 2011;141:900 908 Rate of Progression of Hepatic Fibrosis in Patients With Chronic Hepatitis C: Results From the HALT-C Trial JOHN C. HOEFS,* MITCHELL L. SHIFFMAN, ZACHARY D. GOODMAN, DAVID
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationAge, Platelets Count, Serum Cholesterol and Gamma Glutamyl Transpeptidase, as Non Invasive Markers for Liver Fibrosis in Chronic HCV Patients
Age, Platelets Count, Serum Cholesterol and Gamma Glutamyl Transpeptidase, as Non Invasive Markers for Liver Fibrosis in Chronic HCV Patients Hesham Alshabrawi 1 Muhamad M.Abdelghafar 2 and Mohamad A.
More informationTitle: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment
Title: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment Authors: Yolanda Sánchez-Torrijos, Jara Eloísa Ternero Vega, Carmen Cepeda Franco
More informationBio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis
AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using
More informationComparison of FIB-4 and APRI indices as a non-invasive markers for fibrosis in chronic HCV infection. Research Institute, Giza, Egypt
Comparison of FIB-4 and APRI indices as a non-invasive markers for fibrosis in chronic HCV infection Moataz Hassanien 1, Maged EL-Ghannam 1, Moataz Siam 1, Hoda Abu Taleb 2, Medhat EL-Sahhar 3, Ahmed Abdel
More informationTransient elastography the state of the art
Transient elastography the state of the art Laurent CASTERA, MD PhD Department of Hepatology, Hôpital Beaujon, Clichy Université Paris-7, France White Nights of Hepatology, St Petersburg, Russia, june
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationEuropean. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes
supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza
More informationEvaluation and Staging of Liver Fibrosis
Hepatitis C Online PDF created October 31, 2018, 2:08 pm Evaluation and Staging of Liver Fibrosis This is a PDF version of the following document: Section 2: Evaluation, Staging, and Monitoring of Chronic
More informationHepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
More informationSimple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
1 Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle upon Tyne, UK 2 Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne,
More informationRole of microbubble ultrasound contrast agents in the non-invasive assessment of chronic hepatitis C-related liver disease
PO Box 2345, Beijing 100023, China World J Gastroenterol 2006 June 14; 12(22): 3461-3465 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2006 The WJG Press. All rights reserved. EDITORIAL
More informationHEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS
HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS Essam A. Wahab*, Talaat Fathy** Sameh Saber*** and Hanan S. Ahmad**** Internal Medicine*,
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationStudy of Some Serum Biochemical Markers of Liver Fibrosis in Patients with Chronic HCV
Research Article imedpub Journals www.imedpub.com Journal of Clinical Gastroenterology and Hepatology DOI: 10.21767/2575-7733.1000010 Study of Some Serum Biochemical Markers of Liver Fibrosis in Patients
More informationYun Jung Kim, Byoung Kuk Jang, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho, Woo Jin Chung, and Jae Seok Hwang
The Korean Journal of Hepatology 2012;18:41-47 http://dx.doi.org/10.3350/kjhep.2012.18.1.41 pissn: 1738-222X eissn: 2093-8047 Original Article Rapid normalization of alanine aminotransferase predicts viral
More information